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Abstract
The increasing availability of complete influenza virus genomes is deepening our understanding of influenza evolutionary
dynamics and facilitating the selection of vaccine strains. However, only one complete African influenza virus sequence is
available in the public domain. Here we present a complete genome analysis of 59 influenza A/H3N2 viruses isolated from
humans in Uganda during the 2008 and 2009 season. Isolates were recovered from hospital-based sentinel surveillance for
influenza-like illnesses and their whole genome sequenced. The viruses circulating during these two seasons clearly differed
from each other phylogenetically. They showed a slow evolution away from the 2009/10 recommended vaccine strain (A/
Brisbane/10/07), instead clustering with the 2010/11 recommended vaccine strain (A/Perth/16/09) in the A/Victoria/208/09
clade, as observed in other global regions. All of the isolates carried the adamantane resistance marker S31N in the M2 gene
and carried several markers of enhanced transmission; as expected, none carried any marker of neuraminidase inhibitor
resistance. The hemagglutinin gene of the 2009 isolates differed from that of the 2008 isolates in antigenic sites A, B, D, and
to a lesser extent, C and E indicating evidence of an early phylogenetic shift from the 2008 to 2009 viruses. The internal
genes of the 2009 isolates were similar to those of one 2008 isolate, A/Uganda/MUWRP-050/2008. Another 2008 isolate had
a truncated PB1-F2 protein. Whole genome sequencing can enhance surveillance of future seasonal changes in the viral
genome which is crucial to ensure that selected vaccine strains are protective against the strains circulating in Eastern Africa.
This data provides an important baseline for this surveillance. Overall the influenza virus activity in Uganda appears to mirror
that observed in other regions of the southern hemisphere.
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Introduction
Clinical surveillance and genetic analysis are invaluable in
guiding effective influenza control measures. In sub-Saharan
Africa, however, most outbreaks of influenza go unreported and
information about circulating strains is relatively limited [1].
Partial sequences and strain information are currently available
from only a few countries in Africa which increased their
surveillance efforts after the emergence of influenza A, H5N1, in
humans in 2003 [2,3]. The 2009 H1N1 influenza pandemic
underscored the importance of surveillance networks that can
rapidly characterize circulating viruses for effective response and
containment [4].
Influenza A viruses evolve rapidly; this characteristic allows
them to regularly generate new strains to which human immunity
is lacking, thereby causing periodic pandemics [5]. Of the 16
known subtypes of hemagglutinin (HA) and nine subtypes of
neuraminidase (NA) in influenza A viruses [6] only subtypes H3N2
and H1N1 currently circulate in the human population. In Sub-
Saharan Africa, H3N2 was the predominant subtype in 2009,
when the swine-origin influenza A (H1N1) virus was introduced
into the human population [7]. The two virus subtypes are
currently co-circulating [8].
Minor mutations in the eight gene segments of influenza A
viruses, especially the HA segment, can alter viral antigenic
epitopes sufficiently to evade immune recognition (antigenic drift)
[9]. In some cases, different viruses co-circulating in the same host
can exchange entire gene segments, resulting in re-assortment of
the genome and generating new virus strains (antigenic shift) [10].
These changes can produce more fit viruses that cause new
epidemics or pandemics. Vaccination is the principal strategy to
reduce the public health burden of influenza, but its effectiveness
depends on influenza surveillance and full genome analysis of the
viruses isolated [11]. Although influenza vaccination is very
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that have undergone vaccination pressure are frequently intro-
duced from other regions [12].
Most influenzasequencinghasfocusedontheHA1domainofthe
hemagglutinin gene, where mutations have the greatest effect on
antigenic structure [7]. However, sequencing of the whole influenza
virus genome facilitates comparison and understanding of the
evolutionary dynamics of circulating viruses and the prediction of
potential evolutionevents that arelikely to result in new strains [13].
It also allows closer examination of the importance of other genes in
influenza outbreaks and vaccine selection. A detailed examination
of the whole genomes of some recent H3N2 viruses revealed that
multiple lineages can co-circulate, persist, and re-assort in
epidemiologically significant ways that are not easily discerned by
examining the HA genes alone [14,15]. Holmes and colleagues [15]
demonstrated that some H3N2 isolates could not be distinguished
on the basis of their HA genes but could be assigned to different
clades on the basis of their seven other gene segments. Therefore,
whole genome sequencing allows better monitoring of evolutionary
events that can predict the emergence of viruses with pandemic
potential (Fricke [16,17] and subsequently provides vital data on
global viral spread better informing control strategies. Here, we
describe the whole genome analysis of influenza A/H3N2 viruses
isolated in Uganda during the 2008 and 2009 seasons and compare
these viruses with other African isolates and with the pertinent
WHO reference vaccine strains.
Materials and Methods
Sample collection
Samples were collected at two Ugandan sentinel surveillance sites
established in2008:Mulago National Referral Hospitalin Kampala
and Kayunga District Hospital in Kayunga District. Nasopharyn-
geal and throatsamples were collected from individuals 6 months or
more of age with influenza-like symptoms at the two facilities’
outpatient clinics from October 1, 2008 through September 30,
2009. Inclusion criteria were fever ($38uC) plus either cough or
sore throat within the past 72 hours prior to patient presentation.
Any patient too ill to participate or unwilling or unable to provide
consent to participate in the surveillance study was excluded. All
participants/caretakers were informed about the study and
consented to participate in the study by signing (or by a thumbprint
if unable to write) a consent form if 18 yrs or older signed. For
children aged less than 18 yrs, their parents/guardians signed the
informed consent form while for minors aged 8 to 17 yrs, they
together with their parents/guardians signed the consent form.
Nasopharangeal and throat swab samples were collected using a
dacron swab in a 2-ml cryovial containing virus transport medium.
After collection, the samples were immediately stored at 2196uCi n
a liquid nitrogen dry shipper or kept on ice if the samples were to be
delivered to the laboratory in less than 8 hours. All samples were
transported to Makerere University Walter Reed Influenza
Research Laboratories (daily from Mulago Hospital and within
one week from Kayunga Hospital). Sample collection at these
surveillance sites began in October 2008, and specimens analyzed
for this study were collected from this time through September
2009. The study was approved by the Makerere University School
of Public Health Institutional Review Board, the US Army
Research and Material Command, and the Uganda National
Council for Science and Technology.
Influenza A screening by RT-PCR
Viral RNA was extracted from all samples by using the
QIAamp Viral RNA mini kit (Qiagen) according to the
manufacturer’s directions. RT-PCR of the extracts was performed
by using a Qiagen One-Step RT-PCR kit according to the
manufacturer’s instructions, with the following influenza A matrix
gene primers M52C forward: 59CTTCTAACCGAGGTC-
GAAACG-39 and M253R reverse: 59-AGGGCATTT TGGA-
CAAAKCGTCTA-39 (TAGc, Copenhagen) as described [18].
(Screening for flu B was simultaneously done by Flu-B M-gene
specific primers but data is not included in this paper except the
relative occurrence). Briefly, the 25-ml reaction volume contained
5 mlo f5 6 PCR buffer, 13 ml of RNAse-free H20, 1 mlo f
10 mmol/L dNTPs, 1.5 ml of 10 nmol/L reverse primer, 1.5 mlo f
10 nmol/L forward primer, 1 ml of enzyme mix (Taq DNA
polymerase and reverse transcriptase), and 2 ml of viral RNA
extract. Amplification was carried out in an Applied Biosystems
Veriti 96-well thermocycler with a single reverse transcription step
of 50uC for 30 min, ‘‘hot start PCR’’ (95uC) for 15 sec, forty 30-
sec denaturation cycles at 95uC, 30 sec of primer annealing at
55uC, 1 min of extension at 72uC, and further extension for
10 min at 72uC. The samples (including a known positive control)
were then separated on a 1% agarose gel with a 50-bp marker.
The primers amplified a 250-bp segment of the matrix gene in
influenza A–positive samples; this product was visualized and
documented in a Biorad Gel Doc XR imager.
Virus isolation and subtyping
PCR-positive samples (100 ml) were inoculated on 70%–90%
confluent Madin-Darby Canine Kidney cell line (MDCK) (NBL2;
American Type Culture Collection,(ATCC) Rockville, Md.) in
flat-sided tubes after pre-treatment with TPCK trypsin to facilitate
virus entry. Tubes were capped loosely, incubated in a tissue
culture incubator at 37uC with 5% CO2, and observed daily for 10
days for cytopathic effects by light microscopy using an inverted
microscope. When cytopathic effects were observed, 10 mlo f
supernatant fluid was placed in the chamber of a multiwell slide
and allowed to dry. Influenza virus was confirmed by immuno-
fluorescence assay with antibodies against influenza A or B. The
isolates were subtyped by RT-PCR using primers specific for H3,
H1, (from CDC) and N1, and N2 as previously described [19]. All
isolates were stored at 280uC until further characterization.
Sequencing and sequence analysis
The influenza H3N2 isolates isolated during this period were
sequenced at the WHO Collaborating Center for the Ecology of
Influenza in Animals and the NIAID Center of Excellence in
Influenza Research and Surveillance (CEIRS) at St. Jude
Children’s Research Hospital, Memphis, TN. Isolates were
sequenced by using next-generation DNA technologies (Illumina
Genome Analyzer) according to the manufacturer’s instructions.
To amplify all eight segments in a single reaction, RT-PCR was
conducted on RNA templates using Uni-12, Uni-13, and
polymerase gene primers as previously described [20] plus
Invitrogen SuperScript III One-Step Reverse Transcriptase and
Platinum Taq HiFi (Invitrogen). Sanger sequencing was carried
out to fill out some of the sequences gaps remaining after illumina
sequencing at the Hartwell Center of St. Jude Children’s Research
Hospital, Memphis, TN.
Sequences were aligned using the Bioedit program [21]. The
eight gene segments were phylogenetically analyzed on the basis of
their nucleotide/protein sequences. The MEGA version 4.0
program [22] was used for tree building by the neighbor-joining
method. The number of bootstrap replications was set to 1,000,
and bootstrap values above 50 were labeled on major tree
branches for reference. The Ugandan virus strains were clustered
on the basis of nucleotides, and only dominant clusters were used
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es from all relevant African human virus isolates available in
GenBank and GISAID databases and the sequences of H3N2
vaccine strains recommended by the World Health Organization
for the 2007, 2008, and 2009 seasons (A/Brisbane/10/2007, A/
Victoria/208/2009, A/Perth/16/2009).
Accession numbers. The genebank sequence accession
numbers for the 444 segments of the 59 isolates included in this
study are from CY087308 though to CY087751.
Results
Patients
During the study period, 932 samples were collected from
consenting patients at the two sentinel sites (733 at Mulago
Hospital and 199 at Kayunga Hospital). The majority (77%) of
study participants were #5 years of age (Table 1). The participants
from whom the samples were collected were all outpatients
presenting with a fever ($38uC) plus either cough or sore throat
within the past 72 hours prior to patient presentation. The rate of
influenza A virus recovery was 7.9% (72 isolates). The distribution
of cases followed the typical tropical seasonal pattern, peaking
during July, August, and September (Fig. 1). The present study
focused on the H3N2 subtype of influenza A. Of the 59 samples
positive for H3N2 influenza virus, only five were from Kayunga
Hospital (all collected in 2008).
Sequence analysis
A total of 444 gene segments from the 59 isolates were analyzed.
Table 2 lists the number of specific gene segments of the 59 isolates
(51 isolates from 2008 and 8 from 2009) that were sequenced.
Nucleotide and amino acid sequences for the whole genome were
compared within the Uganda isolates and between these isolates,
the WHO vaccine strains and available sequences of other African
isolates. The 2008 and 2009 isolates had differences in all eight
gene segments or their encoded proteins. The HA, NA,
nucleoprotein (NP), nonstructural protein 1 (NS1), matrix 1
(M1), and matrix 2 (M2) genes as well as the nonstructural protein
2 (NS2), polymerase acidic (PA), polymerase basic 1 (PB1), PB1-
F2, and PB2 protein sequences also clearly differentiated the two
2008 and 2009 seasons. However, all of the 2009 isolates were
similar to one 2008 isolate: A/Uganda/MUWRP-050/2008
(H3N2) for all but HA genes. Kimura genetic distances between
the 2008 isolates and the 2009 isolates ranged from 0.7% to 1.7%
at the nucleotide level and from 1.7% to 6% at the amino acid
level (Table 2).
Surface glycoprotein genes and gene products
HA gene. The HA coding sequences and amino acid
sequences of the 59 Ugandan isolates were analyzed. All of the
HAs showed the K73Q amino acid (aa) substitution that was
characteristic of the A/H3N2 viruses circulating in most parts of
the world at that time as evidenced by the phyologenetic
comparison to WHO vaccine strain and the other selected
publicly available sequences (Figure 2). Phylogenetic analysis
showed the isolates to cluster into two distinct major clades
corresponding to the year of isolation. The 2008 isolates clustered
with the A/Brisbane/10/2007 vaccine strain, while the 2009
isolates clustered with the A/Victoria/208/2009-like viruses with
the exception of one isolate, A/Uganda/MUWRP-070/2009
(Figure 2). The 2009 isolates differed from the 2008 isolates at two
antigenic sites: antigenic site B, which contained an N189K aa
substitution, and antigenic site D, which showed a T212A
substitution. The 2009 isolates also had other aa substitutions at
antigenic site B: N144S (with the exception of A/Uganda/
MUWRP-070/2009 and A/Uganda/MUWRP-062/2009) and
K158N (with the exception of A/Uganda/MUWRP-070/2009).
In addition, all of the 2009 isolates had a single silent cytosine–to-
adenine nucleotide substitution at position 270, although this
mutation did not result in an amino acid change. A/Uganda/
MUWRP-070/2009 differed from all other isolates in this study in
having an R269K aa substitution, and A/Uganda/MUWRP-
079/2009 differed from all other isolates in having an I192T and
an I245V aa substitution.
All of the isolates had the classical receptor binding site motif
with 19Y, 136S, 153W, 183H, 195Y, and 225–228 NIPS in the
HA protein, although as expected, there were differences in the
antigenic sites. The major differences between the 2008 and 2009
isolates were at antigenic sites A, B, and D. At antigenic site A,
Thirty eight of the 2008 isolates had the IRRSNNS motif, while
the all the others had the IRRSSNS motif. At antigenic site B, the
2008 isolates had the THLKFK motif, while the 2009 isolates had
the THLNFK motif; at antigenic site D, the 2008 isolates had the
VSTKRSQQTVIPNIGSR motif, while the 2009 isolates had the
VSTKRSQQAVIPNIGSR motif.
NA gene. Phylogenetic analysis of the NA genes of the 59
Ugandan isolates also indicated two lineages that clearly
differentiated the 2008 and 2009 isolates (Figure 3). All isolates
were descended from A/Brisbane/10/2007-like viruses, with the
D147N and I215V genetic characteristics. The NA genes of the
2009 isolates differed from those of the 2008 isolates by
substitution of two amino acids: I26T and Y40C (with the
exception of A/Uganda/MUWRP-050/2008). The 2009 isolates
Table 1. Distribution of study participants according to age and sample site.
Age group
(years) Mulago National Referral Hospital: n (%) Kayunga District Hospital: n (%) Total
0–5 657 (89.6%) 69 (34.7%) 726 (77%)
6–17 49 (6.7%) 25 (12.6%) 74 (8%)
18–20 5 (0.7%) 30 (15.1%) 35 (4%)
21–30 6 (0.8%) 27 (13.6%) 33 (4%)
31–40 1 (0.1%) 25 (12.6%) 26 (3%)
.40 0 (0%) 19 (9.5%) 19 (2%)
Not recorded 15 (2.0%) 4 (2.0%) 19 (2%)
Total 733 199 932
doi:10.1371/journal.pone.0027803.t001
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isolates clustered with the A/Brisbane/10/2007-like clade. No
molecular marker of neuraminidase inhibitor resistance was
observed in any of the isolates.
Internal genes and gene products
Various amino acid mutations in the internal gene products
differentiated the 2008 from the 2009 isolates, although some 2008
and 2009 isolates were differentiated only by one or more silent
nucleotide mutations (data not shown) in the internal genes. The
phyolgenetic relationships of the internal genes PB2, PB1, PA, NP,
M, and NS in relation to vaccine reference strains are shown in
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 and Figure
S6, respectively. The aa positions of interest included drug
resistance and increased virulence or enhanced transmission
markers. All isolates had the S31N genetic marker for adamantane
resistance in M2. Several molecular markers of enhanced
transmission similar to other contemporary H3N2 influenza A
viruses were detected in all isolates: A16G and C55F in M2,
S409N in PA, and A199S, A661T, V667I, K702R and E627K
(markers of increased virulence) in PB2. The PB2 D701, a marker
of increased virulence was not observed in any of the isolates. The
PB1-F2 protein of A/Uganda/MUWRP-007/2008 was truncated
at position 28 (verified by re-sequencing the encoding gene twice)
due to a cytosine-to thymine substitution at position 82. In
addition, the PB1-F2 proteins of A/Uganda/MUWRP-062/2009
and A/Uganda/MUWRP-086/2009 were 3 amino acids shorter
than those of the remaining 2008–2009 H3N2 strains.
Discussion
We analyzed the coding sequences of all eight gene segments of
influenza A/H3N2 isolates from the 2008 and 2009 influenza
seasons in Uganda and compared them with those of the WHO-
recommended vaccine strains for the 2009/10 and 2010/11
seasons [7] and with other epidemiologically relevant African
strains from both GenBank and GISAID databases. To our
knowledge, this is the first report of the full genomic sequencing of
influenza viruses isolated in East Africa. We obtained the full
genome sequence of 25 of the 59 Ugandan H3N2 isolates, with 59
full HA, M and NP; 56 full NA; 53 full NS; 44 full PA; 40 full PB1;
and 36 full PB2 sequences. The similarity between Ugandan
strains is such that the available information is sufficient to have an
Table 2. Genetic pair-wise distance matrix for the Ugandan
isolates.
Gene/Protein (no. of
sequences analyzed)
Maximum Kimura 2P
genetic distance (nt
level), %
Maximum Poisson
correction genetic
distance (aa level), %
PB2 (53)
1 1.1 1.6
PB1 (57)
1 1.7 1.8
PB1-F2 (49) - 6.0
PA (58)
1 1.0 1.4
HA (59) 1.2 1.7
NP (59) 0.7 0.4
NA (59) 0.9 1.3
NS (57) 1.2 -
NS1 (57) - 2.0
NS2 (57) - 2.0
M (59) 0.7 -
M1 (59) - 0.8
M2 (59) - 2.1
1Partial sequences were included in the analysis of PB2, PB1, and PA genes.
doi:10.1371/journal.pone.0027803.t002
Figure 1. Distribution of influenza cases from October 1, 2008 through September 30, 2009. The figure shows the two influenza seasons.
The 2008 season was only Flu A and peaked in November while the 2009 season was both FluA and B and peaked in August. Flu A was more
prevalent than Flu B. This paper discusses only Flu A.
doi:10.1371/journal.pone.0027803.g001
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and to compare these East African strains with viruses from
around the world. We found that the 2008 and 2009 isolates were
clearly differentiated by changes in all eight genome segments.
Previous full-genome analyses of influenza viruses have identified
striking differences between the phylogenetic clusters generated for
different gene segments [15]. Most analyses of field isolates have
used the HA1 domain of the HA gene because of its antigenic
importance [2,7]. However, viral fitness is affected not only by the
antigenic properties of the HA gene but also by those of the NA
gene and by the interaction of HA and NA with other viral
proteins [23], each of which plays a significant role in promoting
survival and replication.
The HA gene sequences indicated that all of the 2008 Ugandan
isolates had evolved from A/Brisbane/10/07-like viruses; all of
these viruses carried the signature genetic marker K173Q, and all
of them remained within the A/Brisbane/10/07-like clade. The
2009 isolates appeared to have evolved away from the A/
Brisbane/10/07-like viruses by acquiring the genetic markers
N189K and K158N, which are characteristic of the A/Victoria/
208/09 and A/Perth/16/09-like clades; these markers were
reported in most other H3N2 influenza viruses isolated in Africa
during that year and in many isolates globally. None of the
Ugandan isolates clustered with the A/Perth/16/09-like subclade,
which is defined by the additional substitutions E62K and N144K,
but they all had the T212A substitution defining the A/Victoria/
208/09 subclade [7]. A/Perth/16/09 is the recommended H3N2
reference virus for 2010–11 vaccines for both the northern and
southern hemispheres and was shown to be antigenically similar to
A/Victoria/208/09-like strains (WHO 2010). A number of non-
Ugandan African isolates have clustered in the A/Perth/16/09
subclade. Although there was a clear differentiation between the
2008 and 2009 Ugandan isolates, some of the 2008 isolates
clustered with viruses isolated in other parts of Africa in 2009.
The evolution of all of the Ugandan isolates from the A/
Brisbane/10/07-like viruses was further confirmed by the
presence of the signature genetic markers D147N and I125V in
the NA gene [7]. The NA of influenza viruses plays a role in
liberation of the viral progeny from infected cells and is a target of
the neuraminidase inhibitors. Resistance to neuraminidase
inhibitors is rare among influenza H3N2 isolates [24], and no
markers of such resistance were found in our study.
All of the Ugandan isolates’ internal genes contained markers
that differentiated the 2008 and 2009 isolates, indicating a
polygenic change between the two years. There was one unusual
2008 isolate (A/Uganda/MUWRP-050/2008) whose internal and
NA genes showed many similarities to those of the 2009 isolates
but whose HA gene did not. This isolate appeared to be an
intermediate between the two seasonal strains. The adamantane
resistance reported in most H3N2 viruses worldwide [25] was
confirmed in the Ugandan isolates by an S31N substitution in the
M2 protein. We found no significant changes in the M1 protein,
which is reportedly involved in the generation of virus-like
particles [26,27] and is the most conserved influenza virus protein.
At the nucleotide level, however, there was a silent C175A
substitution that differentiated the 2008 and 2009 isolates.
The RNA polymerase genes PB1, PB2, and PA are involved in
both transcription and replication of the genome. The PB1 gene
encodes an RNA polymerase and a PB1-F2 protein from an
alternative open reading frame [27]. In all of the 2009 isolates, the
PB1-F2 protein had the three amino acid substitutions E4G, I16T,
and N34S, all of which were also reported in human seasonal
H3N2 isolates in Thailand [28]. These changes were also found in
one 2008 isolate, A/Uganda/MUWRP-050/2008. The effect of
these mutations on viral fitness is unknown. The N66S
substitution, which is the only PB1-F2–associated genetic marker
of increased pathogenicity, was not identified. One isolate (A/
Uganda/MUWRP-007/2008) had a truncated, nonfunctional
PB1-F2 protein due to a single nucleotide substitution at position
28. It is suggested that PB1-F2 is not expressed in all influenza
strains, but it is known to play a role in pathogenicity by inducing
apoptosis and exacerbating pro-inflammatory effects [29]. A
truncated PB1-F2 protein has also been reported in other strains,
including the 2009 pandemic H1N1 strain. Further phenotypic
studies are required to determine whether A/Uganda/MUWRP-
007/2008 is less virulent than co-circulating H3N2 strains because
of this PB1-F2 truncation. All of the Ugandan isolates had the
L13P substitution in the PB1 protein, which enhances polymerase
activity and increases virulence by improving PA polymerase
affinity [30], and the I317M substitution in the PB1 protein, which
is reportedly related to increased virulence in mice [31].
The NP gene segments of the studied isolates did not contain
the markers (L136M, N319K) of enhanced transmission. Non-
structural proteins are not components of the viral particles but are
expressed at high levels in infected cells; the T92E substitution in
the NS1 protein has been implicated in pathogenicity and severity
of disease [27], [24].
Overall, the Ugandan influenza A/H3N2 isolates from the 2008
and 2009 influenza seasons phylogenetically clustered separately.
They carried signature markers of the previous vaccine strain A/
Brisbane/10/07 but had continued to evolve and changes could
be observed in all gene segments. The 2009 isolates clustered with
the A/Victoria/208/09 clade and shared some properties with the
A/Perth/16/09. Close follow-up of shifts during future seasons.
Genetic and antigenic drift is responsible for the diversity seen in
contemporary seasonal H3N2. But full genome sequencing can be
Figure 2. Phylogenetic analysis of the influenza A/H3N2 HA genes. The phylogenetic tree shows clustering of the Ugandan isolates into two
distinct major clades corresponding to the year of isolation. The 2008 isolates clustered with the A/Brisbane/10/2007/-like virus clade, while the 2009
isolates clustered with the A/Victoria/208/09-like virus clade, with the exception of one isolate. Also included in the tree are the last 3 recommended
H3N2 vaccine strains (A/Wisconsin/67/2005, A/Brisbane/10/2007, and A/Perth/16/2009, in red font) and other relevant African isolates (at least 1
sequence per country, but excluding identical sequences at the aa level). Ugandan isolates from 2008 and 2009 are shown in green and blue,
respectively. A single strain was kept as a representative of identical sequences, hence there are less than 59 strains represented on the tree. At the
amino acid level, the HA sequences of A/Uganda/MUWRP-03/2008, A/Uganda/MUWRP-08/2008, A/Uganda/MUWRP-09/2008, A/Uganda/MUWRP-10/
2008, A/Uganda/MUWRP-13/2008, A/Uganda/MUWRP-14/2008, A/Uganda/MUWRP-17/2008, A/Uganda/MUWRP-19/2008, A/Uganda/MUWRP-21/
2008, A/Uganda/MUWRP-23/2008, A/Uganda/MUWRP-26/2008, A/Uganda/MUWRP-27/2008, A/Uganda/MUWRP-28/2008, A/Uganda/MUWRP-45/
2008, and A/Uganda/MUWRP-49/2008 were indeed identical to A/Uganda/MUWRP-01/2008 present on the tree; A/Uganda/MUWRP-20/2008 and A/
Uganda/MUWRP-38/2008 to A/Uganda/MUWRP-05/2008; A/Uganda/MUWRP-22/2008, A/Uganda/MUWRP-24/2008, A/Uganda/MUWRP-29/2008, A/
Uganda/MUWRP-42/2008, A/Uganda/MUWRP-43/2008, A/Uganda/MUWRP-44/2008, A/Uganda/MUWRP-48/2008, A/Uganda/MUWRP-50/2008, and A/
Uganda/MUWRP-52/2008 to A/Uganda/MUWRP-06/2008; A/Uganda/MUWRP-40/2008 to A/Uganda/MUWRP-07/2008; A/Uganda/MUWRP-31/2008 to
A/Uganda/MUWRP-15/2008; A/Uganda/MUWRP-35/2008, A/Uganda/MUWRP-36/2008, and A/Uganda/MUWRP-37/2008 to A/Uganda/MUWRP-34/
2008; A/Uganda/MUWRP-47/2008 to A/Uganda/MUWRP-46/2008; and A/Uganda/MUWRP-65/2009 and A/Uganda/MUWRP-86/2009 to A/Uganda/
MUWRP-58/2009.
doi:10.1371/journal.pone.0027803.g002
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27803used for monitoring of reassortment events within H3N2 and
between other Flu A which is vital to ensure that selected vaccine
strains are protective against the strains circulating in this region
[32]. Despite the increasing availability of whole influenza genome
sequences in the developed world, this is the second report to our
knowledge of an analysis of the complete genome sequence of
African influenza isolates and the first such report from East
Africa. This data will be very valuable in tracking the phylogenetic
evolution of influenza viruses within sub-Saharan Africa.
Supporting Information
Figure S1 Phylogenetic analysis of the influenza A/
H3N2 PB2 genes. Most Ugandan 2008–2009 PB2 gene
sequences were identical to A/Uganda/MUWRP-01/2008 at
the amino acid level except for the cluster of A/Uganda/
MUWRP-50/2008 identical to A/Uganda/MUWRP-58/2009,
A/Uganda/MUWRP-62/2009, A/Uganda/MUWRP-75/2009,
A/Uganda/MUWRP-79/2009, and A/Uganda/MUWRP-86/
2009; and the following unique sequences present on the tree:
A/Uganda/MUWRP-6/2008, A/Uganda/MUWRP-8/2008, A/
Uganda/MUWRP-13/2008, A/Uganda/MUWRP-14/2008, A/
Uganda/MUWRP-15/2008, A/Uganda/MUWRP-17/2008, A/
Uganda/MUWRP-19/2008, A/Uganda/MUWRP-20/2008, A/
Uganda/MUWRP-21/2008, A/Uganda/MUWRP-24/2008, A/
Uganda/MUWRP-27/2008, A/Uganda/MUWRP-28/2008, A/
Uganda/MUWRP-35/2008, A/Uganda/MUWRP-36/2008, A/
Uganda/MUWRP-37/2008, A/Uganda/MUWRP-38/2008, A/
Uganda/MUWRP-39/2008, A/Uganda/MUWRP-40/2008, A/
Uganda/MUWRP-41/2008, A/Uganda/MUWRP-42/2008, A/
Uganda/MUWRP-44/2008, A/Uganda/MUWRP-45/2008, A/
Uganda/MUWRP-48/2008, A/Uganda/MUWRP-52/2008, A/
Uganda/MUWRP-61/2009, A/Uganda/MUWRP-65/2009, A/
Uganda/MUWRP-70/2009, and A/Uganda/MUWRP-74/
2009. Our Ugandan PB2 gene sequences (in bold) were compared
to the 2 available vaccine strains A/Wisconsin/67/2005 and A/
Brisbane/10/2007 (in italic and underlined) and all available
African strains (only 2 sequences from Dakar, Senegal). Bootstrap
values .49 are indicated at the tree’s nodes.
(TIF)
Figure S2 Phylogenetic analysis of the influenza A/
H3N2 PB1 genes. Ugandan 2008–2009 PB1 gene sequences
identical to A/Uganda/MUWRP-01/2008 at the amino acid level
were excluded from the tree: A/Uganda/MUWRP-02/2008, A/
Uganda/MUWRP-05/2008, A/Uganda/MUWRP-06/2008, A/
Uganda/MUWRP-08/2008, A/Uganda/MUWRP-09/2008, A/
Uganda/MUWRP-13/2008, A/Uganda/MUWRP-14/2008, A/
Uganda/MUWRP-16/2008, A/Uganda/MUWRP-17/2008, A/
Uganda/MUWRP-24/2008, A/Uganda/MUWRP-26/2008, A/
Uganda/MUWRP-28/2008, A/Uganda/MUWRP-29/2008, A/
Uganda/MUWRP-32/2008, A/Uganda/MUWRP-46/2008, A/
Uganda/MUWRP-47/2008, A/Uganda/MUWRP-48/2008, A/
Uganda/MUWRP-49/2008, and A/Uganda/MUWRP-51/
2008; as were A/Uganda/MUWRP-58/2009, A/Uganda/
MUWRP-61/2009, A/Uganda/MUWRP-65/2009 and A/
Uganda/MUWRP-75/2009 identical to A/Uganda/MUWRP-
50/2008; and A/Uganda/MUWRP-31/2008 and A/Uganda/
MUWRP-33/2008 identical to A/Uganda/MUWRP-15/2008.
Our Ugandan PB1 gene sequences (in bold) were compared to the
2 available vaccine strains A/Wisconsin/67/2005 and A/
Brisbane/10/2007 (in italic and underlined) and all available
African strains (only 2 sequences from Dakar, Senegal). Bootstrap
values .49 are indicated at the tree’s nodes.
(TIF)
Figure S3 Phylogenetic analysis of the influenza A/
H3N2 PA genes. Ugandan 2008–2009 PA gene sequences
identical to A/Uganda/MUWRP-01/2008 at the amino acid level
were excluded from the tree: A/Uganda/MUWRP-03/2008, A/
Uganda/MUWRP-05/2008, A/Uganda/MUWRP-07/2008, A/
Uganda/MUWRP-08/2008, A/Uganda/MUWRP-10/2008, A/
Uganda/MUWRP-11/2008, A/Uganda/MUWRP-16/2008, A/
Uganda/MUWRP-17/2008, A/Uganda/MUWRP-23/2008, A/
Uganda/MUWRP-27/2008, A/Uganda/MUWRP-31/2008, A/
Uganda/MUWRP-33/2008, A/Uganda/MUWRP-38/2008, A/
Uganda/MUWRP-40/2008, A/Uganda/MUWRP-41/2008, A/
Uganda/MUWRP-42/2008, A/Uganda/MUWRP-43/2008,
and A/Uganda/MUWRP-45/2008; as was A/Uganda/
MUWRP-46/2008 identical to A/Uganda/MUWRP-47/2008;
A/Uganda/MUWRP-86/2009 identical to A/Uganda/
MUWRP-61/2009; and A/Uganda/MUWRP-58/2009, A/
Uganda/MUWRP-65/2009, A/Uganda/MUWRP-74/2009, A/
Uganda/MUWRP-75/2009, and A/Uganda/MUWRP-79/2009
identical to A/Uganda/MUWRP-50/2009. Our Ugandan PA
gene sequences (in bold) were compared to the 2 available vaccine
strains A/Wisconsin/67/2005 and A/Brisbane/10/2007 (in italic
and underlined) and all available African strains (only 2 sequences
from Dakar, Senegal). Bootstrap values .49 are indicated at the
tree’s nodes.
(TIFF)
Figure S4 Phylogenetic analysis of the influenza A/
H3N2 NP genes. Ugandan 2008–2009 NP gene sequences were
all identical to A/Uganda/MUWRP-01/2008 at the amino acid
level except for A/Uganda/MUWRP-03/2008, A/Uganda/
MUWRP-05/2008, A/Uganda/MUWRP-16/2008, and A/Uga
nda/MUWRP-23/2008=A/Uganda/MUWRP-45/2008, which
is why only 4 strains appear on the phylogenetic tree. Our
Ugandan NP gene sequences (in bold) were compared to the 2
Figure 3. Phylogenetic analysis of the influenza A/H3N2 NA genes. The phylogenetic tree shows two lineages that differentiate the 2009 and
2008 isolates, although all had the D147N and I215V genetic characteristics of the A/Brisbane/10/2007-like viruses. The NA genes of the 2009 isolates
(in blue) differed from those of the 2008 isolates (in green) by two amino acid substitutions: I26T and Y40C. Vaccine strains A/Brisbane/10/2007 and
A/Perth/16/2009 are shown in red. Relevant African isolates (at least 1 sequence per country, but excluding identical sequences at the aa level) were
also included. A single strain was kept as a representative of identical sequences, hence there are less than 59 strains represented on the tree. At the
amino acid level, the NA sequences of A/Uganda/MUWRP-02/2008, A/Uganda/MUWRP-03/2008, A/Uganda/MUWRP-05/2008, A/Uganda/MUWRP-07/
2008, A/Uganda/MUWRP-10/2008, A/Uganda/MUWRP-11/2008, A/Uganda/MUWRP-13/2008, A/Uganda/MUWRP-14/2008, A/Uganda/MUWRP-16/
2008, A/Uganda/MUWRP-18/2008, A/Uganda/MUWRP-21/2008, A/Uganda/MUWRP-22/2008, A/Uganda/MUWRP-24/2008, A/Uganda/MUWRP-27/
2008, A/Uganda/MUWRP-28/2008, A/Uganda/MUWRP-29/2008, A/Uganda/MUWRP-32/2008, A/Uganda/MUWRP-34/2008, A/Uganda/MUWRP-35/
2008, A/Uganda/MUWRP-36/2008, A/Uganda/MUWRP-37/2008, A/Uganda/MUWRP-38/2008, A/Uganda/MUWRP-40/2008, A/Uganda/MUWRP-41/
2008, A/Uganda/MUWRP-42/2008, A/Uganda/MUWRP-43/2008, A/Uganda/MUWRP-44/2008, A/Uganda/MUWRP-46/2008, A/Uganda/MUWRP-47/
2008, A/Uganda/MUWRP-49/2008, A/Uganda/MUWRP-51/2008, and A/Uganda/MUWRP-52/2008 were indeed identical to A/Uganda/MUWRP-01/2008
present on the tree; A/Uganda/MUWRP-22/2008, A/Uganda/MUWRP-58/2009, A/Uganda/MUWRP-61/2009, A/Uganda/MUWRP-65/2009, A/Uganda/
MUWRP-74/2009, A/Uganda/MUWRP-75/2009, and A/Uganda/MUWRP-79/2009 to A/Uganda/MUWRP-50/2008.
doi:10.1371/journal.pone.0027803.g003
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10/2007 (in italic and underlined) and all available African strains
(only 2 sequences from Dakar, Senegal). Bootstrap values .49 are
indicated at the tree’s nodes.
(TIF)
Figure S5 Phylogenetic analysis of the influenza A/
H3N2 M genes. Most Ugandan 2008–2009 M gene sequences
were identical to A/Uganda/MUWRP-01/2008 at the amino
acid level except for the cluster of A/Uganda/MUWRP-61/2009
identical to A/Uganda/MUWRP-65/2009, A/Uganda/
MUWRP-74/2009, A/Uganda/MUWRP-75/2009, A/Uganda/
MUWRP-79/2009, and A/Uganda/MUWRP-86/2009; A/
Uganda/MUWRP-50/2008 identical to A/Uganda/MUWRP-
58/2009; and the following unique sequences present on the tree:
A/Uganda/MUWRP-16/2008, A/Uganda/MUWRP-18/2008,
A/Uganda/MUWRP-20/2008, A/Uganda/MUWRP-26/2008,
A/Uganda/MUWRP-36/2008, and A/Uganda/MUWRP-70/
2009. Our Ugandan M gene sequences (in bold) were compared
to the 2 available vaccine strains A/Wisconsin/67/2005 and A/
Brisbane/10/2007 (in italic and underlined) and all available
African strains (identical sequences were removed from the
analysis keeping a single representing virus per country). Bootstrap
values .49 are indicated at the tree’s nodes.
(TIF)
Figure S6 Phylogenetic analysis of the influenza A/
H3N2 NS genes. Ugandan 2008–2009 NS gene sequences
identical to A/Uganda/MUWRP-01/2008 at the amino acid level
were excluded from the tree: A/Uganda/MUWRP-06/2008, A/
Uganda/MUWRP-22/2008, A/Uganda/MUWRP-25/2008, A/
Uganda/MUWRP-29/2008, A/Uganda/MUWRP-34/2008, A/
Uganda/MUWRP-36/2008, A/Uganda/MUWRP-40/2008, A/
Uganda/MUWRP-42/2008, A/Uganda/MUWRP-43/2008, A/
Uganda/MUWRP-44/2008, A/Uganda/MUWRP-48/2008,
and A/Uganda/MUWRP-52/2008; as were A/Uganda/
MUWRP-8/2008, A/Uganda/MUWRP-9/2008, A/Uganda/
MUWRP-10/2008, A/Uganda/MUWRP-13/2008, A/Uganda/
MUWRP-14/2008, A/Uganda/MUWRP-17/2008, A/Uganda/
MUWRP-18/2008, A/Uganda/MUWRP-19/2008, A/Uganda/
MUWRP-21/2008, A/Uganda/MUWRP-27/2008, A/Uganda/
MUWRP-28/2008, and A/Uganda/MUWRP-51/2008 identical
to A/Uganda/MUWRP-3/2008; A/Uganda/MUWRP-20/
2008, A/Uganda/MUWRP-32/2008, A/Uganda/MUWRP-38/
2009, and A/Uganda/MUWRP-41/2008 identical to A/
Uganda/MUWRP-11/2008; A/Uganda/MUWRP-31/2008, A/
Uganda/MUWRP-33/2008, and A/Uganda/MUWRP-39/2008
to A/Uganda/MUWRP-15/2008; A/Uganda/MUWRP-23/
2008 to A/Uganda/MUWRP-45/2008; and A/Uganda/
MUWRP-61/2009, A/Uganda/MUWRP-65/2009, A/Uganda/
MUWRP-70/2009, A/Uganda/MUWRP-74/2009, A/Uganda/
MUWRP-75/2009, and A/Uganda/MUWRP-79/2009 to A/
Uganda/MUWRP-58/2009. Our Ugandan NS gene sequences
(in bold) were compared to the 2 available vaccine strains A/
Wisconsin/67/2005 and A/Brisbane/10/2007 (in italic and
underlined) and all available African strains (only 2 sequences
from Dakar, Senegal). Bootstrap values .49 are indicated at the
tree’s nodes.
(TIF)
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